- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07549516
Tutkimus askiminibin siedettävyydestä, turvallisuudesta ja tehokkuudesta potilailla, joilla on Philadelphia-kromosomipositiivinen krooninen myelooinen leukemia kroonisessa vaiheessa Saksassa (ASC2ADHERE)
Ei-interventiivinen tutkimus askiminibin siedettävyydestä, turvallisuudesta ja tehosta vastadiagnosoiduilla ja aiemmin hoidetuilla potilailla, joilla on Philadelphia-kromosomipositiivinen krooninen myelooinen leukemia kroonisessa vaiheessa Saksassa – ASC2ADHERE-tutkimus
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Novartis Pharmaceuticals
- Puhelinnumero: +41613241111
- Sähköposti: novartis.email@novartis.com
Tutki yhteystietojen varmuuskopiointi
- Nimi: Novartis Pharmaceuticals
Opiskelupaikat
-
-
-
Amberg, Saksa, 92224
- Rekrytointi
- Novartis Investigative Site
-
Bad Friedrichshall, Saksa, 74177
- Rekrytointi
- Novartis Investigative Site
-
Bad Liebenwerda, Saksa, 04924
- Rekrytointi
- Novartis Investigative Site
-
Bad Saarow, Saksa, 15526
- Rekrytointi
- Novartis Investigative Site
-
Berlin, Saksa, 10437
- Rekrytointi
- Novartis Investigative Site
-
Berlin, Saksa, 10365
- Rekrytointi
- Novartis Investigative Site
-
Berlin, Saksa, 12552
- Rekrytointi
- Novartis Investigative Site
-
Berlin, Saksa, 10559
- Rekrytointi
- Novartis Investigative Site
-
Berlin, Saksa, 12487
- Rekrytointi
- Novartis Investigative Site
-
Bremerhaven, Saksa, 27568
- Rekrytointi
- Novartis Investigative Site
-
Buchholz Nordheide, Saksa, 21244
- Rekrytointi
- Novartis Investigative Site
-
Cottbus, Saksa, 03046
- Rekrytointi
- Novartis Investigative Site
-
Deggendorf, Saksa, 94469
- Rekrytointi
- Novartis Investigative Site
-
Detmold, Saksa, 32756
- Rekrytointi
- Novartis Investigative Site
-
Dorfen, Saksa, 84405
- Rekrytointi
- Novartis Investigative Site
-
Dortmund, Saksa, 44263
- Rekrytointi
- Novartis Investigative Site
-
Dresden, Saksa, 01307
- Rekrytointi
- Novartis Investigative Site
-
Dresden, Saksa, 01127
- Rekrytointi
- Novartis Investigative Site
-
Düren, Saksa, 52353
- Rekrytointi
- Novartis Investigative Site
-
Erfurt, Saksa, 99085
- Rekrytointi
- Novartis Investigative Site
-
Erfurt, Saksa, 99084
- Rekrytointi
- Novartis Investigative Site
-
Eschweiler, Saksa, 52249
- Rekrytointi
- Novartis Investigative Site
-
Göttingen, Saksa, 37073
- Rekrytointi
- Novartis Investigative Site
-
Hanover, Saksa, 30161
- Rekrytointi
- Novartis Investigative Site
-
Hanover, Saksa, 30625
- Rekrytointi
- Novartis Investigative Site
-
Hildesheim, Saksa, 31135
- Rekrytointi
- Novartis Investigative Site
-
Kiel, Saksa, 24105
- Rekrytointi
- Novartis Investigative Site
-
Leipzig, Saksa, 04103
- Rekrytointi
- Novartis Investigative Site
-
Leverkusen, Saksa, 51375
- Rekrytointi
- Novartis Investigative Site
-
Mutlangen, Saksa, 73557
- Rekrytointi
- Novartis Investigative Site
-
Naunhof, Saksa, 04683
- Rekrytointi
- Novartis Investigative Site
-
Neuss, Saksa, 41462
- Rekrytointi
- Novartis Investigative Site
-
Offenburg, Saksa, 77654
- Rekrytointi
- Novartis Investigative Site
-
Oldenburg, Saksa, 26121
- Rekrytointi
- Novartis Investigative Site
-
Parchim, Saksa, 19370
- Rekrytointi
- Novartis Investigative Site
-
Potsdam, Saksa, 14467
- Rekrytointi
- Novartis Investigative Site
-
Potsdam, Saksa, 14482
- Rekrytointi
- Novartis Investigative Site
-
Schorndorf, Saksa, 73614
- Rekrytointi
- Novartis Investigative Site
-
Schwetzingen, Saksa, 68723
- Rekrytointi
- Novartis Investigative Site
-
Soest, Saksa, 59494
- Rekrytointi
- Novartis Investigative Site
-
Stade, Saksa, 21680
- Rekrytointi
- Novartis Investigative Site
-
Torgau, Saksa, 04860
- Rekrytointi
- Novartis Investigative Site
-
Ulm, Saksa, 89081
- Rekrytointi
- Novartis Investigative Site
-
Wetzlar, Saksa, 35578
- Rekrytointi
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden, Baden-Wurttemberg, Saksa, 76532
- Rekrytointi
- Novartis Investigative Site
-
Heidenheim, Baden-Wurttemberg, Saksa, 89522
- Rekrytointi
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, Saksa, 74523
- Rekrytointi
- Novartis Investigative Site
-
Winnenden, Baden-Wurttemberg, Saksa, 71364
- Rekrytointi
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg, Bavaria, Saksa, 63739
- Rekrytointi
- Novartis Investigative Site
-
Augsburg, Bavaria, Saksa, 86152
- Rekrytointi
- Novartis Investigative Site
-
Donauwörth, Bavaria, Saksa, 86609
- Rekrytointi
- Novartis Investigative Site
-
Herrsching am Ammersee, Bavaria, Saksa, 82211
- Rekrytointi
- Novartis Investigative Site
-
Kempten (Allgäu), Bavaria, Saksa, 87439
- Rekrytointi
- Novartis Investigative Site
-
Landsberg am Lech, Bavaria, Saksa, 86899
- Rekrytointi
- Novartis Investigative Site
-
Munich, Bavaria, Saksa, 81241
- Rekrytointi
- Novartis Investigative Site
-
Munich, Bavaria, Saksa, 81377
- Rekrytointi
- Novartis Investigative Site
-
Regensburg, Bavaria, Saksa, 93053
- Rekrytointi
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven, Free Hanseatic City of Bremen, Saksa, 27576
- Rekrytointi
- Novartis Investigative Site
-
-
Hesse
-
Kassel, Hesse, Saksa, 34125
- Rekrytointi
- Novartis Investigative Site
-
Offenbach, Hesse, Saksa, 63065
- Rekrytointi
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar, Lower Saxony, Saksa, 38642
- Rekrytointi
- Novartis Investigative Site
-
Rotenburg (Wümme), Lower Saxony, Saksa, 27356
- Rekrytointi
- Novartis Investigative Site
-
Twistringen, Lower Saxony, Saksa, 27239
- Rekrytointi
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Saksa, 50674
- Rekrytointi
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Saksa, 50677
- Rekrytointi
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Saksa, 51103
- Rekrytointi
- Novartis Investigative Site
-
Solingen, North Rhine-Westphalia, Saksa, 42653
- Rekrytointi
- Novartis Investigative Site
-
Wesel, North Rhine-Westphalia, Saksa, 46483
- Rekrytointi
- Novartis Investigative Site
-
-
Saxony
-
Zittau, Saxony, Saksa, 02763
- Rekrytointi
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Saksa, 06110
- Rekrytointi
- Novartis Investigative Site
-
Merseburg, Saxony-Anhalt, Saksa, 06217
- Rekrytointi
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Saksa, 23758
- Rekrytointi
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, Saksa, 04600
- Rekrytointi
- Novartis Investigative Site
-
Saalfeld, Thuringia, Saksa, 07318
- Rekrytointi
- Novartis Investigative Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
Kuvaus
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: PROSPECTIVE
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Aikaikkuna: Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Potilaiden osuus hoitavan lääkärin dokumentoiman TKI-hoidon päätöksen syyn mukaan
Aikaikkuna: Lähtötaso
|
Lähtötaso
|
|
|
Potilaiden osuus, joilla annosta pienennettiin annoksen pienentämisen syyn mukaan
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Niiden potilaiden prosenttiosuus, joiden hoito keskeytettiin keskeytyksen syyn mukaan
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Percentage of Patients Who Discontinued Treatment by Reason for Discontinuation
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Aika hoidon lopettamiseen
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Aika hoidon keskeyttämiseen
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Aika annoksen vähentämiseen
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Aika hoidon keskeyttämiseen haittatapahtumien vuoksi (TTDAE)
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
3, 6, 9, 12, 15, 18, 21 ja 24 kuukautta
|
|
|
Percentage of Patients by Clinical Characteristic
Aikaikkuna: Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Aikaikkuna: Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
Aikaikkuna: 3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Aikaikkuna: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Neoplasmat
- Krooninen sairaus
- Sairauden ominaisuudet
- Neoplasmat histologisen tyypin mukaan
- Hematologiset sairaudet
- Leukemia, myeloidi
- Luuydinsairaudet
- Leukemia
- Myeloproliferatiiviset häiriöt
- Patologiset tilat, merkit ja oireet
- Hemic- ja imusuutteet
- Leukemia, myelogeeninen, krooninen, BCR-ABL-positiivinen
Muut tutkimustunnusnumerot
- CABL001J1DE02
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .